Moving to a state with no income tax might seem like a clear financial win, but the reality is more complex. Higher sales, property, and overall living costs in these states often offset the initial paycheck boost, creating a nuanced picture of who truly benefits.
Shares of USA Rare Earth (NASDAQ: USAR) climbed over 6% Monday morning following reports of a proposed U.S. government initiative, dubbed 'Project Vault,' aimed at securing a strategic reserve of critical minerals, including rare earths, to counter potential supply chain vulnerabilities.
Thai troops now occupy a shell-damaged compound in O'Smach, Cambodia, which officials identify as a former hub for international scam operations. A military-led tour revealed a labyrinth of soundproofed call centers, fake police stations, and meticulous scripts, shedding light on a multi-billion dollar criminal enterprise.
Senator James Lankford's annual oversight report details what he calls wasteful federal spending, including controversial NIH-funded projects on transgender-related animal testing and aborted fetal tissue research, reigniting debates on scientific priorities and fiscal responsibility.
With one in twelve salaried employees having worked in multiple countries, Colgate-Palmolive is leveraging international assignments as a core strategy to build agile, globally-minded leadership.
Target's Michael Fiddelke and Walmart's John Furner step into the CEO role, outlining priorities to reinvigorate growth and customer loyalty amid operational and social challenges.
Amidst a turbulent period for craft distilling, the founders of Casey Jones Distillery in Hopkinsville, KY, have sold their bourbon and moonshine operation to Pennsylvania-based B3 Beverage Company, securing the legacy of a family-run business while joining a growing portfolio of craft breweries and distilleries.
Major financial institutions Barclays and Morgan Stanley maintain projections for two interest rate cuts in 2024, despite President Trump's nomination of inflation hawk Kevin Warsh to chair the Federal Reserve. Analysts suggest policy continuity in the near term, though Senate confirmation faces political hurdles.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, ruling the government failed to substantiate its allegations regarding the judge's public comments.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
A major protest against U.S. Immigration and Customs Enforcement (ICE) brought parts of downtown Portland to a standstill Sunday, culminating in a tense confrontation with federal officers outside a detention facility.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
In a candid '60 Minutes' interview, Senator Rand Paul (R-Ky.) sharply criticized the Trump administration's handling of the fatal shooting of Alex Pretti, stating public trust has been irreparably damaged and questioning the impartiality of a federal investigation.
